Time for the Journal Ombudsman?

Time for the Journal Ombudsman? Stricker and Goldberg have had a truly bitter experience;1 unfortunately, many authors had suffered the same. But I think that their criticism of the peer review system is wrongly addressed: the violation of publication ethics--in this case, the maladministration--may be prevented by the journal's appointing of a mediator, the journal's ombudsman. The Lancet did it in 1996; this journal appointed an independent person "to record and, where necessary, to investig

Written byLjiljana Vuckovic-Dekic
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Stricker and Goldberg have had a truly bitter experience;1 unfortunately, many authors had suffered the same. But I think that their criticism of the peer review system is wrongly addressed: the violation of publication ethics--in this case, the maladministration--may be prevented by the journal's appointing of a mediator, the journal's ombudsman. The Lancet did it in 1996; this journal appointed an independent person "to record and, where necessary, to investigate episodes of alleged editorial maladministration when a complainant remains dissatisfied with the journal's first response to criticism."2 This was accepted enthusiastically by a large scientific audience. The annual report, which the ombudsman is obliged to publish, shows that a considerable part of his job is to investigate and solve the problems Stricker and Goldberg had met.3 Perhaps the structural transformation of the sciences will be the end of the peer review system;4 meanwhile, I agree that the initiative of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies